ArticleCancer management and research2026
Jianpi Rougan Method in Support of Lenvatinib Therapy: A Real-World Study on Maintaining Relative Dose Intensity and Mitigating Toxicity-Driven Discontinuation in Intermediate-to-Advanced HCC.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the effects of Jianpi Rougan method on lenvatinib (LEN) relative dose intensity (RDI), toxicity-related treatment discontinuation, and treatment tolerability in intermediate-to-advanced hepatocellular carcinoma (HCC). Methods: A real-world, retrospective study was conducted on 152 intermediate-to-advanced HCC patients receiving LEN. Patients were grouped based on concurrent use of Jianpi Rougan decoction (combined, n = 73) or not (monotherapy, n = 79). Primary endpoints were RDI at weeks 8, 12, and overall, and the proportion of RDI ≥ 80%. Secondary endpoints included toxicity-related discontinuation, adverse events, and short-term efficacy (objective response rate, ORR; disease control rate, DCR). Propensity score matching (PSM, 1:1) was employed to balance baseline confounders. Results: After PSM (65 pairs, n = 130), baseline characteristics were balanced. The combined group showed significantly higher RDI at week 12 ( Conclusion: Jianpi Rougan method combined with LEN was associated with improved RDI, lower rates of toxicity-related treatment discontinuation, and enhanced treatment persistence in real-world practice, supporting its role as a feasible integrative strategy to maintain targeted therapy intensity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.